原文出处:Positive Results from the Second Phase III SAkuraStar Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in The Lancet Neurology

原标题:罕见病新药!罗氏IL-6单抗satralizumab视神经脊髓炎谱系障碍(NMOSD)3期临床显著降低复发风险!
本文来源自生物谷,更多资讯请下载生物谷APP(
http://www.bioon.com/m/)




























